Dual-Targeting Mechanism Overcomes Immunosuppressive Microenvironments in Cold Solid Tumors
On November 10, 2026, the European Society for Medical Oncology (ESMO) released updated clinical data from the multinational ORION-2 Phase II oncology trial; the next-generation bispecific T-cell engager antibody achieved a 73 percent disease control rate among heavily pretreated patients with refractory gastrointestinal solid tumors. Advanced gastrointestinal malignancies, including refractory gastric carcinomas and pancreatic ductal adenocarcinomas, have dense stromal desmoplasia and profound immunosuppression; conventional single-agent checkpoint inhibitors routinely fail to induce robust tumor regression. The investigational bispecific antibody is a dual-affinity construct engineered to bind Claudin 18.2 on malignant epithelial cells and CD3 on cytotoxic T lymphocytes simultaneously; by physically bridging killer T cells directly to tumor cells, it bypasses peripheral immune tolerance.
Among 120 evaluable trial participants, the verified objective response rate reached 38 percent under RECIST 1.1 criteria. Several metastatic patients experienced volumetric tumor shrinkages exceeding 50 percent within twelve weeks of initial infusion.
Grade 3 or higher cytokine release syndrome occurred in less than 4 percent of treated patients, with zero treatment-related mortalities documented during the monitoring window. The majority of observed adverse reactions were classified as low-grade transient nausea, mild maculopapular rash, and transient transaminase elevations that resolved rapidly under standard supportive interventions; patient-reported physical quality-of-life scores remained stable.
Clinical sponsors initiated patient recruitment across North America, Europe, and the Asia-Pacific region for a global confirmatory Phase III registration study. The pivotal randomized Phase III protocol aims to enroll over 800 patients whose disease progressed following first-line systemic fluoropyrimidine therapy, measuring overall survival against standard second-line chemotherapy. In parallel, the sponsor submitted formal applications for Breakthrough Therapy Designation to the United States Food and Drug Administration and the European Medicines Agency. Longitudinal patient follow-up remains ongoing.
